Kenneth L. Davis is the executive vice chairperson of the board of trustees at the Mount Sinai Health System in New York City,[1][2] and an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease.

In 2003, Davis was appointed dean of Mount Sinai School of Medicine and held that position until 2007, when he was succeeded by Dennis S. Charney, M.D.

[10][11] Awards and recognition Davis participated in breakthrough proof-of-concept studies and clinical trials of cholinesterase inhibitors.

These trials (the first multicenter ones for cholinesterase inhibitors) established efficacy and ultimately led to the first four of the five FDA-approved compounds for treating the symptoms of Alzheimer's: tacrine, rivastigmine, galantamine, donepezil and memantine[15][5] In 1978, Davis, together with Richard Mohs, conducted the first well-controlled study of a drug that was shown able to improve the storage and retrieval functions of long-term memory in humans.

[19] Davis's work on schizophrenia has shown that oligodendroglia cells and myelin play roles in the disease's pathophysiology[20] and that dopamine – long thought to be merely hyperactive in a schizophrenic brain – is actually hypoactive in different regions.